Press Releases

Tevogen Bio announces partnership with BioCentriq, a New Jersey based cell and gene therapy development and manufacturing center, to support clinical manufacturing of Tevogen’s investigational COVID-19 treatment. Under the partnership, experts from both entities will collaborate at BioCentriq’s state-of-the art GMP facilities to produce Tevogen’s proprietary COVID-19 targeted T cells. The teams will utilize the processes and technology required to ensure that all q

Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and the industry’s most robust and expansive lipid nanoparticle (LNP) patent estate, announced that it has entered into a global collaboration and license agreement with Takeda Pharmaceutical Company Limited (“Takeda”) for the discovery, development and commercialization of LNP-delivered nucleic acid therapeutics directed to previously inaccessible drug targets in hepatic stellate cells to

InteRNA Technologies, a clinical-stage biotech company developing microRNA (miRNA)-based therapeutics with a focus on cancer, today announced that it was awarded a Clinical Innovation Credit of € 2.7 Million from the Dutch government. This award will support the clinical validation of the Company’s lead candidate, INT-1B3, for the treatment of solid tumors. The funding is granted by the ‘Rijksdienst voor Ondernemend Nederland’/The Netherlands Enterprise Agency (RVO), an

Denali Therapeutics Inc., a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases,  announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ETV:IDS (DNL310) for the treatment of patients with Hunter syndrome (MPS II). DNL310, Denali’s lead investigational brain-penetrant enzyme replacement therapy, is under evaluation in a Phase 1/2 study

DemeRx IB, Inc. (DemeRx), an atai Life Sciences (atai) platform company focused on developing ibogaine for the treatment of opioid use disorder (OUD), announced the company has approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to commence subject enrollment in a Phase 1/2a clinical trial of ibogaine HCl (DMX-1002). Ibogaine is a naturally-occurring psychedelic product isolated from a West African shrub that has demonstrated rapid and sustained efficacy

Enveric Biosciences, a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, announced that it has acquired an exclusive, perpetual license from Diverse Biotech, a biopharmaceutical company focused on developing new molecules for treating oncology and other debilitating diseases. Enveric plans to research and develop these new drugs with the goal of alleviating the side effects that cancer patients experience. Through the co

A post-pandemic pharma report from CPhI predicts the next few years will deliver strong growth in pharma innovation, with oncology and rare diseases potentially the biggest beneficiaries of positive covid legacies – including accelerated development timelines, remote trials and new technologies in genetic and target screening. The report anticipates breakthroughs in multi-modal disease therapies within five years, mRNA platforms to transform many new non-infectious disease tre

SciSparc Ltd., a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced it has entered an agreement with The Sheba Fund for Health Services and Research, to perform a pre-clinical study for the evaluation of the Company's SCI-210 drug development program, a proprietary novel pharmaceutical preparation containing non-psychoactive cannabinoid cannabidiol  (CBD)and palmitoylethanolamide (PEA) for the treatment of Sta

IONTAS Limited and FairJourney Biologics S.A (FJB)., leaders in the discovery and optimisation of fully human antibodies, have announced that they have entered into an agreement with Quell Therapeutics Limited (Quell) regarding IONTAS / FJB’s proprietary libraries and technology platforms. Quell is harnessing the suppressive capacity of Tregs to develop engineered Treg cell therapies to address several conditions of immune dysfunction. Under the terms of the agreement, IONTAS

Takeda Pharmaceutical Co., Ltd. and is committed to developing drugs that change the fate of patients with rare diseases of the nervous system The biopharmaceutical company Ovid Therapeutics Inc. announced that Takeda has reached an exclusive agreement. According to the agreement, Takeda will obtain from Ovid the global rights to develop and commercialize the drug under development soticlestat (TAK-935/OV935) when the agreement is signed, which can be used to treat Dravet syndrome (DS) and Le